Related Experiment Video
Updated: Jan 6, 2026

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis
Published on: November 21, 2013
Status dystonicus: management and prevention in children at high risk
Alessandro Iodice1, Francesco Pisani
1Unit of Child Neurology and Psychiatry, Santa Chiara Hospital, Trento, Italy. alle.iodice@gmail.com.
Insights
Status dystonicus (SD) is a critical movement disorder emergency. Early recognition of subtle signs and prompt management of triggers can prevent intensive care needs in at-risk children.
Area of Science:
- Neurology
- Movement Disorders
- Pediatric Neurology
Background:
- Status dystonicus (SD) is an under-recognized and undertreated neurological emergency.
- It is associated with significant morbidity and life-threatening events, often requiring intensive care.
- Lack of a standard definition and delayed identification of triggers contribute to its undertreatment.
Purpose of the Study:
- To review clinical features and genetic disorders associated with SD.
- To identify precipitating and trigger factors for SD.
- To propose pharmacological treatment strategies to prevent hospitalization.
Main Methods:
- Critical review of existing literature on Status dystonicus.
- Analysis of clinical features, genetic predispositions, and trigger factors.
- Evaluation of potential pharmacological interventions.
Main Results:
- Genetic links include TOR1A mutations, ARX/GNAO1 variants, and PANK2.
- Key recognition signs: fever, tachycardia, respiratory changes, hypertension, sweating, autonomic instability, elevated CK.
- Primary triggers: pain, fever, dehydration. Sleep and clonidine are potential treatments.
Conclusions:
- Early identification of subtle signs in high-risk children is crucial for better management.
- Preventing or quickly controlling trigger factors can avoid intensive care.
- Proactive management strategies can improve outcomes for Status dystonicus.
Background:
Status dystonicus (SD) is a movement disorder emergency associated with significant morbidity and life-threatening events that requires immediate and effective treatment. Nevertheless, SD is currently an under-recognized and undertreated condition, partly due to the lack of a standard definition and because it can be the acute complicated course of both primary and secondary dystonias. In subjects with SD, due to the delay of identification and lacking prevention of trigger and precipitant factors, intensive care management is consistently required.
Objectives:
We performed a critical review of this topic, outlining clinical features and linked genetic disorders to recognize subject at higher risk of SD, describing precipitant and trigger factors and proposing potential pharmacological treatment strategies in order to prevent hospitalization.
Results:
Genetic predisposition included: primary dystonias particularly in the case of TOR1A mutation; epileptic encephalopathy such as ARX and GNAO1 genetic variants and neurodegenerative disorders as PANK2. Early recognition of SD should be oriented by the following sign and symptoms: fever, tachycardia, respiratory change, hypertension, sweating and autonomic instability, elevated serum CK. Pain, fever and dehydration are main trigger factors that have to be prevented or quickly controlled. Achieving sleep could be the first therapeutic option in those with high risk of developing SD. Recently, enteral or transdermal clonidine as safety and efficacy therapeutic alternative was proposed.
Conclusion:
Recognizing high risk children for Status dystonicus from the onset of subtle signs and avoiding trigger factors could drive towards better management avoiding intensive treatments.
More Related Videos
10:41Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
Published on: September 12, 2020
07:20Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
Published on: August 9, 2024
Related Concept Videos
Dysrhythmias VII: Nursing Management of Dysrhythmias
Mania and Antimanic Drugs: Overview
Skeletal Muscle Relaxants: Therapeutic Uses
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Mitral Stenosis IV: Nursing Management
Depolarizing Blockers: Pharmocokinetics